Can Fite Financials
| CANF Stock | USD 1.55 0.02 1.31% |
Can |
Understanding current and past Can Fite Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Can Fite's financial statements are interrelated, with each one affecting the others. For example, an increase in Can Fite's assets may result in an increase in income on the income statement.
Can Fite Stock Summary
Can Fite competes with ImmuCell, Compugen, Evogene, Collplant Biotechnologies, and Protalix Biotherapeutics. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people.| Foreign Associate | Israel |
Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NYSE MKT Exchange |
| ISIN | US13471N2018 |
| CUSIP | 13471N102 13471N201 13471N300 |
| Location | Israel |
| Business Address | 26 Ben Gurion |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.canfite.com |
| Phone | 972 3 924 1114 |
| Currency | USD - US Dollar |
Can Fite Key Financial Ratios
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 | ||||
| Target Price | 14.0 | ||||
| Beta | 0.57 |
Can Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Can Fite competition to find correlations between indicators driving Can Fite's intrinsic value. More Info.Can Fite Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Can Fite by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Can Fite Biopharma Systematic Risk
Can Fite's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Can Fite volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Can Fite Biopharma correlated with the market. If Beta is less than 0 Can Fite generally moves in the opposite direction as compared to the market. If Can Fite Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Can Fite Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Can Fite is generally in the same direction as the market. If Beta > 1 Can Fite moves generally in the same direction as, but more than the movement of the benchmark.
About Can Fite Financials
What exactly are Can Fite Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Can Fite's income statement, its balance sheet, and the statement of cash flows. Potential Can Fite investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Can Fite investors may use each financial statement separately, they are all related. The changes in Can Fite's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Can Fite's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Can Fite January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Can Fite help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Can Fite Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Can Fite Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Can Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Can Fite's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 27.75 | |||
| Value At Risk | (6.34) | |||
| Potential Upside | 6.29 |
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |